Vioquest Pharmaceuticals 

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical entity that concentrates on obtaining, developing, and marketing drug therapies in clinical stages, specifically targeting oncology and infectious diseases. Its primary product, Xyfid, is currently being advanced for both the management and prevention of hand-foot syndrome. The company's pipeline also features VQD-002, a nucleoside analog presently in Phase I clinical trials for cancer treatment. Another key compound is Lenocta, a small molecule designed to inhibit various protein tyrosine phosphatases, which is progressing through Phase IIa clinical studies for indications like melanoma, renal cell carcinoma, and other solid tumors. Beyond its therapeutic drug development, VioQuest Pharmaceuticals offers chiral products, specialized technology, and bespoke synthesis development services. These services are provided to pharmaceutical and fine chemical companies at different stages of their product lifecycles. The firm was established in 2000 and operates from its corporate headquarters in Basking Ridge, New Jersey.